Flag of the European Union EU Clinical Trials Register Help

Clinical trials for vre

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: vre. Displaying page 1 of 1.
    EudraCT Number: 2019-000244-10 Sponsor Protocol Number: EGBAB Start Date*: 2019-12-13
    Sponsor Name:Region Uppsala
    Full Title: Influence of antibiotic treatment on the normal flora and the presence of resistance genes in known carriers of ESBL and VRE
    Medical condition: Carriage of genes coding for vancomycin resistant enterococci (VRE) and extended spectrum betalactamase producing enterobacteriales (EPE) phenotypes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002346-32 Sponsor Protocol Number: SB-2-004-005 Start Date*: 2015-11-27
    Sponsor Name:Synthetic Biologics, Inc.
    Full Title: A Phase 2b Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of Clostridium difficile Associated Diarrhea in Patients with a Diag...
    Medical condition: Prevention of Clostridium difficile infection (CDI), Clostridium difficile associated diarrhea (CDAD), antibiotic-associated diarrhea (AAD) and secondary infections with healthcare-acquired drug-re...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10006834 C.difficile diarrhea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-001900-76 Sponsor Protocol Number: PRASCO Start Date*: 2015-08-25
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: Manipulating the microbiome in IBD by antibiotics and fecal microbiota transplantation (FMT): a randomized controlled trial
    Medical condition: Acute Severe colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045283 UC aggravated LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005483-25 Sponsor Protocol Number: SMT19969/C003 Start Date*: 2014-10-08
    Sponsor Name:Summit (Oxford) Limited
    Full Title: A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200 mg BID) for 10 days Compared with Fidaxomicin (200 mg BID) for 10 days f...
    Medical condition: Clostridium difficile infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-004333-42 Sponsor Protocol Number: SISPCT Start Date*: Information not available in EudraCT
    Sponsor Name:Friedrich-Schiller-University of Jena
    Full Title: Prospective randomized clinical multicenter trial about the effect of an adjunctive intravenous treatment with sodium selenite (selenase®T, double-blind) and a procalcitonin guided causal therapy (...
    Medical condition: severe sepsis / septic shock
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002604-41 Sponsor Protocol Number: WP6-282512 Start Date*: 2014-01-31
    Sponsor Name:University Medical Centre Utrech
    Full Title: RGNOSIS: Ecological Effects of Decolonisation Strategies in Intensive Care
    Medical condition: Colonisation and Infection with (multi drug resistant) Gram negative bacteria in ICU patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000875-37 Sponsor Protocol Number: VanC-IT Start Date*: 2022-11-03
    Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
    Full Title: A Prospective, Randomized, Placebo-controlled Clinical Trial of oral vancomycin in adults and young adults (15-17 years old) affected by Primary Sclerosing Cholangitis with or without Inflammatory ...
    Medical condition: Primary Sclerosing Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10036732 Primary sclerosing cholangitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000508-13 Sponsor Protocol Number: 72779 Start Date*: 2020-10-27
    Sponsor Name:Princess Máxima Center for Pediatric Oncology
    Full Title: An open-label, randomized clinical trial on teicoplanin infection prophylaxis in pediatric patients with acute myeloid leukemia
    Medical condition: Acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10024346 Leukemia myeloblastic acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Ongoing) DK (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000203-89 Sponsor Protocol Number: NeoVanc Start Date*: 2016-07-18
    Sponsor Name:Fondazione PENTA Onlus
    Full Title: Multi-centre, randomised, open label, phase IIb study to compare the efficacy, safety and pharmacokinetics (PK) of an optimised dosing to a standard dosing regimen of vancomycin in neonates and inf...
    Medical condition: Neonatal late onset sepsis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10053598 Late onset neonatal sepsis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended) EE (Ongoing) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005281-30 Sponsor Protocol Number: DUR001-306 Start Date*: 2016-11-03
    Sponsor Name:Allergan Ltd.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Sk...
    Medical condition: Acute bacterial skin and skin structure infection. For Cohort 5 (from birth to less than 3 months) also patients with sepsis are allowed.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10066412 Staphylococcus aureus skin infection LLT
    20.0 10021881 - Infections and infestations 10037633 Pyoderma (skin infection) LLT
    20.1 10021881 - Infections and infestations 10040873 Skin infection aggravated LLT
    20.0 10021881 - Infections and infestations 10040872 Skin infection PT
    20.0 10021881 - Infections and infestations 10040875 Skin infection pyogenic LLT
    20.0 10021881 - Infections and infestations 10040874 Skin infection NOS LLT
    20.1 10021881 - Infections and infestations 10066409 Staphylococcal skin infection PT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) BG (Completed) GR (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003048-21 Sponsor Protocol Number: Uni-Köln-1667 Start Date*: 2014-03-10
    Sponsor Name:University of Cologne
    Full Title: CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR)
    Medical condition: Immunocompromised patients at high risk of bloodstream infections with colonizing bacteria.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10066481 Hematological malignancy LLT
    16.1 100000004865 10067862 Allogeneic stem cell transplantation LLT
    16.1 100000004870 10054990 Immunodeficiency secondary to organ transplantation LLT
    16.1 100000004870 10021458 Immunodeficiency secondary to transplantation chemotherapy LLT
    16.1 100000004870 10021452 Immunodeficiency secondary to chemotherapy (excl corticosteroids) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001200-12 Sponsor Protocol Number: A5951002 Start Date*: 2007-08-27
    Sponsor Name:Pfizer Global Research and Development
    Full Title: Linezolid In The Treatment Of Complicated Skin And Soft Tissue Infections Proven To Be Due To Methicillin-Resistant Staphylococcus Aureus
    Medical condition: Complicated skin and soft tissue infections
    Disease: Version SOC Term Classification Code Term Level
    10049582
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005159-32 Sponsor Protocol Number: A5951105 Start Date*: 2005-04-28
    Sponsor Name:Pfizer Limited
    Full Title: Linezolid vs Vancomycin/Cefazolin in the treatment of hemodialysis patients with catheter-related gram-positive bloodstream infections
    Medical condition: Catheter-related Gram-positive bloodstream infections.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10007810 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Prematurely Ended) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 24 02:18:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA